New medication for the treatment of drug-resistant tuberculosis are available in Turkmenistan

Ashgabat, Mar 2, 2018: The development of new medicines for treatment tuberculosis (TB) has been making great progress over the past ten years. The World Health Organization has recommended new medications: Bedaquiline and Delamanid for the treatment of resistant tuberculosis. Multiple drug resistance (MDR-TB) is a form of tuberculosis in which bacteria become resistant to two main first-line drugs – isoniazid and rifampicin. Extensively drug resistance (XDR-TB) is a heavier form of tuberculosis when bacteria become resistant to drugs in both the first and second lines. Each year about 500,000 people worldwide fall ill with MDR-TB, of which 10% - XDR-TB. Until recently, there were very few medications with good efficacy to treat drug-resistant tuberculosis. Treatment lasts up to two years with possible side effects, while only 50% of MDR-TB patients and 28% of patients with XDR-TB are cured. In addition, the treatment of resistant TB forms costs between $4,000 and $9,000 per patient.

Bedaquiline is the first in 40 years innovative medication for the treatment of tuberculosis. The effect of its administration occurs within 12 weeks after the start of treatment, while other medicines show results after only 18-24 months. Delamanid is a new medication for the treatment of tuberculosis. During the treatment with Delamanid the improvement of sputum occurs within 2 months of therapy. Successful treatment of resistant tuberculosis with the use of Delamanid is higher than with the treatment of similar medication, i.e. side effects occur rarer and the mortality rate is lower.

Due to the new medications, for the first time in the last 40 years patients with drug-resistant tuberculosis have a chance to cure. However, according to data of 2017, less than five percent of patients worldwide received treatment with these medications. Other patients with drug-resistant tuberculosis continue to be treated with the use of older, more toxic drugs.

In Turkmenistan, under the Global Fund grant, the new effective medications for the treatment of drug-resistant tuberculosis have been available since 2017. The cost of Bedaquiline for the treatment of one patient is $3,000, and the cost of Delamanid - $1,700, however these and other medications for the treatment of tuberculosis are provided free of charge. Bedaquiline and Delamanid combined with other so-called “reserve” drugs for the treatment of multidrug-resistant tuberculosis: clofazimine, linezolid, Imipenem, that are also available in Turkmenistan.

Access to new medications in Turkmenistan is possible due to the fact that the Government provides all possible support to the national tuberculosis control program and creates favorable conditions for the introduction of innovative methods of diagnosis and treatment of tuberculosis.

Contact person:

Nazik Avlyakulova
Communications Associate
nazik.avlyakulova@undp.org

SubscribeSubscribe

Other News

  • Let’s talk SDGs with academia and students

    Let’s talk SDGs with academia and students

    16-18 October 2018, Ashgabat, Turkmenistan. United Nations in Turkmenistan and SDG Center held 3-days workshop on Sustainable Development Goals for academia and students at the Institute of the International Relations of the Ministry of Foreign Affairs of Turkmenistan.

  • University students debate universal healthcare at the United Nations Day Student Debate Tournament

    University students debate universal healthcare at the United Nations Day Student Debate Tournament

    9 October 2018, Ashgabat, Turkmenistan. Universal healthcare, youth health habits, model state health policy and healthcare taxation were all topics debated by students from six university at the United Nations Day Student Debate Tournament hosted at the International University for Humanities and Development. The Tournament was organized by UNFPA, United Nations Population Fund jointly with all United Nations agencies on the occasion of the upcoming United Nations Day.

  • Impact investment workshop attracts more bank and private sector

    Impact investment workshop attracts more bank and private sector

    10-12 October 2018, Ashgabat, Turkmenistan: The State Bank for Foreign Economic Relations of Turkmenistan, UK Embassy and United Nations are hosting a workshop on Impact Investment financing for Sustainable Development Goals. The workshop has attracted about fifty representatives of bank system and private sector in Yyldyz hotel.

  • UN participates at granting citizenship to stateless in Turkmenistan

    UN participates at granting citizenship to stateless in Turkmenistan

    October 1, 2018, Ashgabat, Turkmenistan. The ceremony of handing Turkmen passports over to the stateless persons in Turkmenistan was held at the State Migration Service of Turkmenistan. The ceremony followed the Decree of the President of Turkmenistan signed on 24 (or 25?) September by which the citizenship of Turkmenistan was grated to 735 people.